deltatrials
Unknown PHASE1 INTERVENTIONAL 1-arm NCT05569057

A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Conditions Advanced Solid Tumor Cutaneous T-cell Lymphoma (CTCL)
Interventions SIM1811-03
Updated 4 times since 2022 Last updated: Oct 6, 2022 Started: Sep 30, 2022 Primary completion: Jun 1, 2024 Completion: Mar 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Solid Tumor and Cutaneous T-cell Lymphoma (CTCL), this trial is ongoing. The trial is conducted by Jiangsu Simcere Pharmaceutical Co., Ltd. and has accumulated 4 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshotRecruiting~May 2025 – present · 14 months · monthly snapshotUnknown

Change History

4 versions recorded

  1. May 2025 — Present [monthly]

    Unknown PHASE1

    Status: Recruiting → Unknown

  2. Sep 2024 — May 2025 [monthly]

    Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  4. Nov 2022 — Jul 2024 [monthly]

    Recruiting PHASE1

    First recorded

Sep 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jiangsu Simcere Pharmaceutical Co., Ltd.
Data source: Jiangsu Simcere Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations